1273-GZMK+ T Cells as Biomarkers for Immunotherapy Response

This research identifies granzyme K (GZMK) expression in T cells as a critical biomarker for predicting success in neoadjuvant cancer immunotherapies. By analyzing single-cell data from head and neck cancer patients, the study reveals that GZMK+ progenitor T cells recently recruited from the blood represent a state of high antitumor immunocompetence. Successful treatment outcomes are strongly linked to the efficient differentiation of these cells into active effectors within the tumor microenvironment. Furthermore, the authors developed a GZMK gene signature that accurately forecasts patient response and survival across multiple diverse cancer types. These findings suggest that monitoring T-cell maturation stages can help clinicians personalize immunotherapy strategies more effectively. In summary, the presence and transformation of these specific immune cells serve as a predictive map for how well a patient will fight their disease.References:Sievers, C.M., Chang, TG., Robbins, Y. et al. GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapy. npj Precis. Onc. 10, 237 (2026). https://doi.org/10.1038/s41698-026-01437-7前往小宇宙评论区与主播互动